Effect of tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin on advanced gastric cancer with liver metastasis and its influence on serum matrix metalloproteinase 9 and vascular endothelial growth factor

Abstract

Objective To investigate the clinical efficacy of tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin in the treatment of patients with advanced gastric cancer and liver metastases. Methods From January 2012 to February 2017, 125 patients with advanced gastric cancer and liver metastases in the Second People's Hospital of Jiande were selected and randomly divided into control group and observation group.The control group(63 cases) was treated with tegafur, gimeracil and oteracil porassium capsules.The observation group(62 cases) was treated with tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin.The clinical efficacy of the two groups was evaluated, and the adverse reactions during the treatment were recorded.The serum levels of matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF) were measured before and after treatment. Results The total effective rate of the observation group was 80.64%(50/62), which was significantly higher than 57.14%(36/63) of the control group (χ2=8.294, P=0.015). The incidence rate of adverse reaction in the observation group was 22.58%(14/62), which was significantly lower than 47.61%(30/63) in the control group (χ2=8.588, P=0.003). After treatment, the levels of MMP-9 and VEGF in the two groups were significantly lower than those before treatment (all P=0.000). The MMP-9 and VEGF levels in the observation group were significantly lower than those in the control group(t=14.203, 1.560, P=0.000, 0.000). Conclusion The efficacy of tegafur, gimeracil and oteracil porassium capsules combined with oxaliplatin in the treatment of advanced gastric cancer with liver metastasis is significant and has less adverse reactions. Key words: Stomach neoplasms; Neoplasm metastasis; Matrix metalloproteinase 9; Vascular endothelial growth factors; Antineoplastic combined chemotherapy protocols; Ticino; Oxaliplatin